About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

0.7194 -0.0117 (-1.60%)

Streaming Delayed Price Updated: 1:28 PM EST, Dec 22, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atossa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Are Shares Of Atossa Therapeutics Up Today? ↗

December 11, 2025

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.

Via Benzinga

Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track ↗

December 11, 2025

Via Stocktwits

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

December 11, 2025

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

August 29, 2025

Via ACCESS Newswire

MicroMarvel - Atossa Therapeutics ↗

April 06, 2024

Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals

Via Talk Markets

Atossa Therapeutics backing Endoxifen in the fight against breast cancer

August 23, 2023

--News Direct--

Via News Direct

Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

August 01, 2025

Via ACCESS Newswire

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

June 05, 2025

Via Benzinga

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 20, 2025

Via ACCESS Newswire

Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 02, 2025

Via ACCESS Newswire

Earnings Scheduled For March 25, 2025 ↗

March 25, 2025

Via Benzinga

Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday ↗

September 11, 2024

Via Benzinga

ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024 ↗

August 12, 2024

ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗

July 11, 2024

These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.

Via InvestorPlace

3 Penny Stock Moonshots with 300%+ Upside Potential by 2025 ↗

July 03, 2024

If you understand the risks of penny stocks with upside, you may want to investigate these three stocks today.

Via InvestorPlace

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗

June 07, 2024

These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.

Via InvestorPlace

3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off ↗

May 20, 2024

With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation.

Via InvestorPlace

Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ↗

May 17, 2024

With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.

Via InvestorPlace

ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024 ↗

May 13, 2024

ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar ↗

May 09, 2024

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider.

Via InvestorPlace

ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023 ↗

April 01, 2024

ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market ↗

January 16, 2024

In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.

Via InvestorPlace

This Drug Developer Is Dedicated To "Transforming The Breast Cancer Paradigm" ↗

October 24, 2023

Dr. Steven Quay MD, PhD, President & CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga.

Via Benzinga

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

September 18, 2023

Via ACCESSWIRE

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment ↗

September 15, 2023

One in eight women will be diagnosed with breast cancer during

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 08, 2023

Via Benzinga

Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst ↗

September 08, 2023

Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ: ATOS) with an Overweight rating and

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 08, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023 ↗

September 08, 2023

Via Benzinga

Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer? ↗

August 09, 2023

Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

All News about Atossa Therapeutics, Inc. - Common Stock

Sections

Services

Contact Information

Follow Us